Member Info for roses

From the webcast - modi PFS should be available in 3 to 6 months that will be the time to engage further with partnering/licensing agreements with the major pharmaceutical companies.

First of the delayed buys starting to show now, there really isn’t any need to hide trades like these in the first place !

Not only that, the mm’s are struggling to keep control now.

C11 - one of the issues we will have to deal with now, after such an upbeat and positive update the usual handful of posters will now double down and have to put in extra time to try and erode confidence.

I mentioned a couple of days ago that it will be interesting to see who ups their efforts.

Interesting to hear them confirm that a Nasdaq listing has been discussed and considered and will be done once the time is right.

Burble, yes I noticed that, he stopped himself just in time !

I have to disagree, when blockbuster status was mentioned, the analysts were the ones advocating for scancell to go it alone, and I got the impression that they have already got someone lined up.

Thanks vd, I’m trying to do 2 jobs at once so I’ve missed many many more positive points.

104 documents sent to fda just before Xmas, they took a breath and approved with zero issues, Herculean effort on our side and confidence on theirs

“There will be a lot of news coming from the company apart from scib1”

“Could the results improve from here”

Answer “yes”

Analysts on the questions now saying due to the outstanding results, scancell would be better off doing it alone.

Sath replies by saying due to its blockbuster status other options are being considered.

Lots to report on but without a doubt the best and most upbeat presentations they have ever done.

He’s “very proud as it’s a very rare beast that the fda approves in a way they have with ours.”

Anticipates accelerated approval as well.

Already planning on a post study analysis after the drug is on the market !

Looking very positive

Wow, what a PFS CHART

Look at the difference in the delta!

More delayed chunky buys being shown now, just goes to show that if you have the cash the mm’s will accommodate you at the expense of the short term traders.

Trinity delta -

On track for two milestone payments this year

“ Alongside the ImmunoBody results which have captured investor attention, the Moditope platform continues to progress. Modi-1 is under evaluation in a Phase II trial for squamous cell cancer of head and neck (SSCHN) and renal cell carcinoma (RCC). The results of these cohorts, exploring Modi-1 in combination with CPIs, are on track for data read outs in H126. Similarly, GlyMabs continue to deliver; the lead in-house programme, SC134, is generating positive feedback from the regulatory agencies for clinical development in small cell lung cancer (SCLC) and the two programmes partnered with Genmab are still expected to deliver milestones during 2026.”

Trinity research-

“ The main event in H126 was the impressive data read-outs from the Phase II SCOPE study of SCIB1/iSCIB1+ in combination with doublet checkpoint inhibitors (nivolumab and ipilimumab) in advanced melanoma. Progression free survival (PFS), the key metric, was 74% at 16 months and was a critical factor in the FDA’s rapid clearance of the IND for the Phase III trial of iSCIB1+ (plus doublet CPI). This registrational study is expected to start in calendar 2026, subject to securing the relevant funding, with results and potential commercialisation within three years. Management is evaluating a number of financing options, including partnering discussions, as the strength of the data has stimulated both industry and investor interest.”

Indeed, they dropped the price yesterday to fill quite a few large buys as shown after the close.

Cracking example of shares being transferred from the bored to the astute.